Selective androgen receptor modulators as improved androgen therapy for advanced breast cancer

Steroids

Volumn 90, Issue , 2014, Pages 94-100

  Coss, Christopher C ^a   Jones, Amanda ^a   Dalton, James T ^a  

^a GTx Inc   (United States)

Author keywords

Androgen; Breast; Cancer; Nonsteroidal; Receptor

Indexed keywords

ANDROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BREAST NEOPLASMS; FEMALE; HORMONE SUBSTITUTION; HUMAN;

ANDROGENS; BREAST NEOPLASMS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 84908687006     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2014.06.010     Document Type: Article

References (99)

1. J.T. Dalton, A. Mukherjee, Z. Zhu, L. Kirkovsky, and D.D. Miller Discovery of nonsteroidal androgens Biochem Biophys Res Commun 244 1998 1 4
2. M.L. Mohler, C.E. Bohl, A. Jones, C.C. Coss, R. Narayanan, and Y. He Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit J Med Chem 52 2009 3597 3617
3. A. Negro-Vilar Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium J Clin Endocrinol Metab 84 1999 3459 3462
4. X. Zhang, J.C. Lanter, and Z. Sui Recent advances in the development of selective androgen receptor modulators Expert Opin Ther Pat 19 2009 1239 1258
5. J.T. Dalton, K.G. Barnette, C.E. Bohl, M.L. Hancock, D. Rodriguez, and S.T. Dodson The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial J Cachexia Sarcopenia Muscle 2 2011 153 161
6. A.S. Dobs, R.V. Boccia, C.C. Croot, N.Y. Gabrail, J.T. Dalton, and M.L. Hancock Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial Lancet Oncol 14 2013 335 345
7. A. Jones, J. Chen, D.J. Hwang, D.D. Miller, and J.T. Dalton Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception Endocrinology 150 2009 385 395
8. A. Jones, D.J. Hwang, C.B. Duke 3rd, Y. He, A. Siddam, and D.D. Miller Nonsteroidal selective androgen receptor modulators enhance female sexual motivation J Pharmacol Exp Ther 334 2010 439 448
9. C.L. Shufelt, and G.D. Braunstein Testosterone and the breast Menopause Int 14 2008 117 122
10. G.R. Cuna, A. Calciati, M.R. Strada, C. Bumma, and L. Campio High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose-response evaluation Tumori 64 1978 143 149
11. F. Daniel, D.G. Rao, and C.J. Tyrrell A pilot study of stanozolol for advanced breast carcinoma Cancer 67 1991 2966 2968
12. P. Pronzato, D. Amoroso, A. Ardizzoni, G. Bertelli, P.F. Conte, and A. Michelotti A phase II study with danazol in metastatic breast cancer Am J Clin Oncol 10 1987 407 409
13. G.P. Risbridger, I.D. Davis, S.N. Birrell, and W.D. Tilley Breast and prostate cancer: more similar than different Nat Rev Cancer 10 2010 205 212
14. S.R. Denmeade, and J.T. Isaacs A history of prostate cancer treatment Nat Rev Cancer 2 2002 389 396
15. O. Hiort Clinical and molecular aspects of androgen insensitivity Endocr Dev 24 2013 33 40
16. C. Chang, S.O. Lee, R.S. Wang, S. Yeh, and T.M. Chang Androgen receptor (AR) physiological roles in male and female reproductive systems: lessons learned from AR-knockout mice lacking AR in selective cells Biol Reprod 89 2013 21
17. C. Huggins, and C.V. Hodges Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941 J Urol 168 2002 9 12
18. N.E. Eaton, G.K. Reeves, P.N. Appleby, and T.J. Key Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies Br J Cancer 80 1999 930 934
19. Endogenous H, Prostate Cancer Collaborative G, Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008;100:170-183.
20. P.A. Berry, N.J. Maitland, and A.T. Collins Androgen receptor signalling in prostate: effects of stromal factors on normal and cancer stem cells Mol Cell Endocrinol 288 2008 30 37
21. A.N. Vis, and F.H. Schroder Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways BJU Int 104 2009 438 448
22. S.J. McPherson, H. Wang, M.E. Jones, J. Pedersen, T.P. Iismaa, and N. Wreford Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland Endocrinology 142 2001 2458 2467
23. W.A. Ricke, S.J. McPherson, J.J. Bianco, G.R. Cunha, Y. Wang, and G.P. Risbridger Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling FASEB J 22 2008 1512 1520
24. J.J. Bianco, S.J. McPherson, H. Wang, G.S. Prins, and G.P. Risbridger Transient neonatal estrogen exposure to estrogen-deficient mice (aromatase knockout) reduces prostate weight and induces inflammation in late life Am J Pathol 168 2006 1869 1878
25. X. Li, E. Nokkala, W. Yan, T. Streng, N. Saarinen, and A. Warri Altered structure and function of reproductive organs in transgenic male mice overexpressing human aromatase Endocrinology 142 2001 2435 2442
26. Bosland MC. A perspective on the role of estrogen in hormone-induced prostate carcinogenesis. Cancer Lett 2012.
27. G.S. Prins, and K.S. Korach The role of estrogens and estrogen receptors in normal prostate growth and disease Steroids 73 2008 233 244
28. J.F. Couse, and K.S. Korach Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 20 1999 358 417
29. J.H. Krege, J.B. Hodgin, J.F. Couse, E. Enmark, M. Warner, and J.F. Mahler Generation and reproductive phenotypes of mice lacking estrogen receptor beta Proc Natl Acad Sci USA 95 1998 15677 15682
30. G.S. Prins, L. Birch, J.F. Couse, I. Choi, B. Katzenellenbogen, and K.S. Korach Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: studies with alphaERKO and betaERKO mice Cancer Res 61 2001 6089 6097
31. J.F. Couse, S.C. Hewitt, D.O. Bunch, M. Sar, V.R. Walker, and B.J. Davis Postnatal sex reversal of the ovaries in mice lacking estrogen receptors alpha and beta Science 286 1999 2328 2331
32. S. Dupont, A. Krust, A. Gansmuller, A. Dierich, P. Chambon, and M. Mark Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes Development 127 2000 4277 4291
33. D.M. Attia, and A.G. Ederveen Opposing roles of ERalpha and ERbeta in the genesis and progression of adenocarcinoma in the rat ventral prostate Prostate 72 2012 1013 1022
34. D. Price, B. Stein, P. Sieber, R. Tutrone, J. Bailen, and E. Goluboff Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial J Urol 176 2006 965 970 [discussion 70-1]
35. A.W. Nelson, W.D. Tilley, D.E. Neal, and J. Carroll Estrogen receptor beta in prostate cancer: friend or foe? Endocr Relat Cancer 2014
36. J.F. Couse, and K.S. Korach Exploring the role of sex steroids through studies of receptor deficient mice J Mol Med (Berl) 76 1998 497 511
37. R. Autorino, S. Perdona, M. D'Armiento, M. De Sio, R. Damiano, and L. Cosentino Gynecomastia in patients with prostate cancer: update on treatment options Prostate Cancer Prostatic Dis 9 2006 109 114
38. E. Anderson, and R.B. Clarke Steroid receptors and cell cycle in normal mammary epithelium J Mammary Gland Biol Neoplasia 9 2004 3 13
39. M.C. Pike, D.V. Spicer, L. Dahmoush, and M.F. Press Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk Epidemiol Rev 15 1993 17 35
40. M.S. Rothman, N.E. Carlson, M. Xu, C. Wang, R. Swerdloff, and P. Lee Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography-tandem mass spectrometry Steroids 76 2011 177 182
41. R.B. Clarke, A. Howell, C.S. Potten, and E. Anderson Dissociation between steroid receptor expression and cell proliferation in the human breast Cancer Res 57 1997 4987 4991
42. S. Li, B. Han, G. Liu, S. Li, J. Ouellet, and F. Labrie Immunocytochemical localization of sex steroid hormone receptors in normal human mammary gland J Histochem Cytochem 58 2010 509 515
43. S. Curtis Hewitt, J.F. Couse, and K.S. Korach Estrogen receptor transcription and transactivation: Estrogen receptor knockout mice: what their phenotypes reveal about mechanisms of estrogen action Breast Cancer Res 2 2000 345 352
44. T.E. Hickey, J.L. Robinson, J.S. Carroll, and W.D. Tilley Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Mol Endocrinol 26 2012 1252 1267
45. K.A. Walters, U. Simanainen, and D.J. Handelsman Molecular insights into androgen actions in male and female reproductive function from androgen receptor knockout models Hum Reprod Update 16 2010 543 558
46. S. Yeh, Y.C. Hu, P.H. Wang, C. Xie, Q. Xu, and M.Y. Tsai Abnormal mammary gland development and growth retardation in female mice and MCF7 breast cancer cells lacking androgen receptor J Exp Med 198 2003 1899 1908
47. A.A. Peters, W.V. Ingman, W.D. Tilley, and L.M. Butler Differential effects of exogenous androgen and an androgen receptor antagonist in the peri- and postpubertal murine mammary gland Endocrinology 152 2011 3728 3737
48. P. Philibert, F. Audran, C. Pienkowski, I. Morange, B. Kohler, and E. Flori Complete androgen insensitivity syndrome is frequently due to premature stop codons in exon 1 of the androgen receptor gene: an international collaborative report of 13 new mutations Fertil Steril 94 2010 472 476
49. Q.B. She, S. Chandarlapaty, Q. Ye, J. Lobo, K.M. Haskell, and K.R. Leander Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling PLoS One 3 2008 e3065
50. M. Wasielewski, F. Elstrodt, J.G. Klijn, E.M. Berns, and M. Schutte Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines Breast Cancer Res Treat 99 2006 97 101
51. J.P. Garay, and B.H. Park Androgen receptor as a targeted therapy for breast cancer Am J Cancer Res 2 2012 434 445
52. S. Ando, F. De Amicis, V. Rago, A. Carpino, M. Maggiolini, and M.L. Panno Breast cancer: from estrogen to androgen receptor Mol Cell Endocrinol 193 2002 121 128
53. S.N. Birrell, J.M. Bentel, T.E. Hickey, C. Ricciardelli, M.A. Weger, and D.J. Horsfall Androgens induce divergent proliferative responses in human breast cancer cell lines J Steroid Biochem Mol Biol 52 1995 459 467
54. M. Lippman, G. Bolan, and K. Huff The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture Cancer Res 36 1976 4610 4618
55. D.T. Zava, and W.L. McGuire Human breast cancer: androgen action mediated by estrogen receptor Science 199 1978 787 788
56. J. Szelei, J. Jimenez, A.M. Soto, M.F. Luizzi, and C. Sonnenschein Androgen-induced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptor Endocrinology 138 1997 1406 1412
57. R.E. Hall, S.N. Birrell, W.D. Tilley, and R.L. Sutherland MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level androgen receptor expression Eur J Cancer 30A 1994 484 490
58. A.A. Peters, G. Buchanan, C. Ricciardelli, T. Bianco-Miotto, M.M. Centenera, and J.M. Harris Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer Cancer Res 69 2009 6131 6140
59. R.E. Hall, J.O. Aspinall, D.J. Horsfall, S.N. Birrell, J.M. Bentel, and R.L. Sutherland Expression of the androgen receptor and an androgen-responsive protein, apolipoprotein D, in human breast cancer Br J Cancer 74 1996 1175 1180
60. S. Park, J. Koo, H.S. Park, J.H. Kim, S.Y. Choi, and J.H. Lee Expression of androgen receptors in primary breast cancer Ann Oncol 21 2010 488 492
61. J.A. Soreide, O.A. Lea, J.E. Varhaug, A. Skarstein, and S. Kvinnsland Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment Eur J Surg Oncol 18 1992 112 118
62. I. Castellano, E. Allia, V. Accortanzo, A.M. Vandone, L. Chiusa, and R. Arisio Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers Breast Cancer Res Treat 124 2010 607 617
63. R. Hu, S. Dawood, M.D. Holmes, L.C. Collins, S.J. Schnitt, and K. Cole Androgen receptor expression and breast cancer survival in postmenopausal women Clin Cancer Res 17 2011 1867 1874
64. S. Park, J.S. Koo, M.S. Kim, H.S. Park, J.S. Lee, and J.S. Lee Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers Ann Oncol 22 2011 1755 1762
65. J.Y. Tsang, Y.B. Ni, S.K. Chan, M.M. Shao, B.K. Law, and P.H. Tan Androgen receptor expression shows distinctive significance in er positive and negative breast cancers Ann Surg Oncol 2014
66. F. Kassam, K. Enright, R. Dent, G. Dranitsaris, J. Myers, and C. Flynn Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design Clin Breast Cancer 9 2009 29 33
67. L.J. McGhan, A.E. McCullough, C.A. Protheroe, A.C. Dueck, J.J. Lee, and R. Nunez-Nateras Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype Ann Surg Oncol 21 2014 361 367
68. J. He, R. Peng, Z. Yuan, S. Wang, J. Peng, and G. Lin Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray Med Oncol 29 2012 406 410
69. J.L. Robinson, S. Macarthur, C.S. Ross-Innes, W.D. Tilley, D.E. Neal, and I.G. Mills Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1 EMBO J 30 2011 3019 3027
70. D. Tang, S. Xu, Q. Zhang, and W. Zhao The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer Med Oncol 29 2012 526 533
71. F.E. Adair, and J.B. Herrmann The use of testosterone propionate in the treatment of advanced carcinoma of the breast Ann Surg 123 1946 1023 1035
72. I.S. Goldenberg Testosterone propionate therapy in breast cancer JAMA 188 1964 1069 1072
73. B.J. Kennedy Fluoxymesterone therapy in advanced breast cancer N Engl J Med 259 1958 673 675
74. D. Jones, E.H. Cameron, K. Griffiths, E.N. Gleave, and A.P. Forrest Steroid metabolism by human breast tumours Biochem J 116 1970 919 921
75. S.S. Legha, H.L. Davis, and F.M. Muggia Hormonal therapy of breast cancer: new approaches and concepts Ann Intern Med 88 1978 69 77
76. O.H. Pearson, A. Manni, and B.M. Arafah Antiestrogen treatment of breast cancer: an overview Cancer Res 42 1982 3424s 3429s
77. C.D. West, B.L. Damast, S.D. Sarro, and O.H. Pearson Conversion of testosterone to estrogens in castrated, adrenalectomized human females J Biol Chem 218 1956 409 418
78. E. Heinonen, A. Alanko, P. Grohn, and P. Rissanen Nandrolone decanoate added to tamoxifen in the treatment of advanced breast cancer Breast Cancer Res Treat 5 1985 75 80
79. A.S. Doane, M. Danso, P. Lal, M. Donaton, L. Zhang, and C. Hudis An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen Oncogene 25 2006 3994 4008
80. A. Gucalp, S. Tolaney, S.J. Isakoff, J.N. Ingle, M.C. Liu, and L.A. Carey Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer Clin Cancer Res 19 2013 5505 5512
81. R. Dent, M. Trudeau, K.I. Pritchard, W.M. Hanna, H.K. Kahn, and C.A. Sawka Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 2007 4429 4434
82. D.J. Perrault, D.M. Logan, D.J. Stewart, V.H. Bramwell, A.H. Paterson, and E.A. Eisenhauer Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study Invest New Drugs 6 1988 207 210
83. T.P. Zhao, and G.F. He A phase II clinical trial of flutamide in the treatment of advanced breast cancer Tumori 74 1988 53 56
84. F. Moinfar, M. Okcu, O. Tsybrovskyy, P. Regitnig, S.F. Lax, and W. Weybora Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies Cancer 98 2003 703 711
85. Y. Ogawa, E. Hai, K. Matsumoto, K. Ikeda, S. Tokunaga, and H. Nagahara Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers Int J Clin Oncol 13 2008 431 435
86. F.E. Vera-Badillo, A.J. Templeton, P. de Gouveia, I. Diaz-Padilla, P.L. Bedard, and M. Al-Mubarak Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis J Natl Cancer Inst 106 2014 djt319
87. J.J. Lai, P. Chang, K.P. Lai, L. Chen, and C. Chang The role of androgen and androgen receptor in skin-related disorders Arch Dermatol Res 304 2012 499 510
88. H.F. Escobar-Morreale, E. Carmina, D. Dewailly, A. Gambineri, F. Kelestimur, and P. Moghetti Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society Hum Reprod Update 18 2012 146 170
89. D. Ferriman, and J.D. Gallwey Clinical assessment of body hair growth in women J Clin Endocrinol Metab 21 1961 1440 1447
90. J.A. Simon Safety of estrogen/androgen regimens J Reprod Med 46 2001 281 290
91. J. Zhang, Y. Sun, Y. Liu, Y. Sun, and D.J. Liao Synergistic effects of androgen and estrogen on the mouse uterus and mammary gland Oncol Rep 12 2004 709 716
92. L. Liu, Y. Li, N. Xie, O. Shynlova, J.R. Challis, and D. Slater Proliferative action of the androgen receptor in human uterine myometrial cells-a key regulator for myometrium phenotype programming J Clin Endocrinol Metab 98 2013 218 227
93. S.R. Goldstein The endometrial echo revisited: have we created a monster? Am J Obstet Gynecol 191 2004 1092 1096
94. T. Van den Bosch, D. Van Schoubroeck, L. Ameye, J. De Brabanter, S. Van Huffel, and D. Timmerman Ultrasound assessment of endometrial thickness and endometrial polyps in women on hormonal replacement therapy Am J Obstet Gynecol 188 2003 1249 1253
95. L. Fitzsimmons, and S.A. Hadley The metabolic response to injury in the surgical/trauma patient Dimens Crit Care Nurs 10 1991 4 12
96. O.A. Lea, S. Kvinnsland, and T. Thorsen Improved measurement of androgen receptors in human breast cancer Cancer Res 49 1989 7162 7167
97. D. Narita, M. Raica, C. Suciu, A. Cimpean, and A. Anghel Immunohistochemical expression of androgen receptor and prostate-specific antigen in breast cancer Folia Histochem Cytobiol 44 2006 165 172
98. E. Amir, B. Seruga, S. Niraula, L. Carlsson, and A. Ocana Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis J Natl Cancer Inst 103 2011 1299 1309
99. P.E. Lonning, and H.P. Eikesdal Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved Endocr Relat Cancer 20 2013 R183 R201